Invus
Investor profile
Investment firmVenture capital
Also recorded as: Invus fund
Deals
23
distinct rounds
Companies
17
backed
Active span
2009–2025
17 yrs
Total round €
€1.1B
sum of rounds joined
Deals by year
distinct rounds / yearTop sectors
by dealsStages
by dealsCountries
by dealsCo-investment network
shared roundsHover a node for shared-deal counts; click a co-investor to open its profile.
Frequent co-investors
shared rounds- Sofinnova Partners5
- Lifeline Ventures3
- Sunstone Capital3
- Andera Partners2
- Avidity Partners2
- Balderton Capital2
- Deep Track Capital2
- Forbion2
- Gilde Healthcare2
- Intel Capital2
- Jeito Capital2
- Novo Holdings2
- Omega Funds2
- Piper Heartland Healthcare Capital2
- Polaris Partners2
- RA Capital Management2
- Schroders Capital2
- UPMC Enterprises2
- Access Biotechnology1
- Adamed Technology1
- Asabys Partners1
- Avoro Capital Advisors1
- Blast1
- Bluebird Ventures1
- BNP Paribas Développement1
Portfolio
top 30 by total round €| Company | Country | Rounds | Total € |
|---|---|---|---|
| Artios | UK | 2 | €229M |
| Noema Pharma | Switzerland | 2 | €135M |
| Hemab Therapeutics | Denmark | 1 | €127M |
| Leyden Labs | Netherlands | 1 | €124M |
| Imcheck Therapeutics | France | 1 | €96M |
| Agomab Therapeutics | Belgium | 1 | €83M |
| KNIME | Switzerland | 3 | €67M |
| FlatFrog Laboratories | Sweden | 3 | €45M |
| Bizagi | UK | 1 | €44M |
| Future Finance | Ireland | 1 | €40M |
| inotrem | France | 1 | €39M |
| Coave Therapeutics | France | 1 | €32M |
| One Biosciences | France | 1 | €15M |
| ZenRobotics | Finland | 1 | €13M |
| aive | France | 1 | €12M |
| The Curious AI | Finland | 1 | €3.3M |
| The curious AI company | Finland | 1 | €800k |
Biggest deals
top 10 by amount| Company | Stage | Amount | Date |
|---|---|---|---|
| Artios | Series C | €129M | 2021-07 |
| Hemab Therapeutics | Series B | €127M | 2023-02 |
| Leyden Labs | Series B | €124M | 2022-01 |
| Noema Pharma | Series B | €106M | 2023-03 |
| Artios | Series D+ | €99M | 2025-11 |
| Imcheck Therapeutics | Other | €96M | 2022-06 |
| Agomab Therapeutics | Series D+ | €83M | 2024-10 |
| Bizagi | Other | €44M | 2017-09 |
| Future Finance | Series C | €40M | 2017-12 |
| inotrem | Series B | €39M | 2019-09 |